C. Lai, J. Dienstag, E. Schiff, N. Leung, M. Atkins et al., Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B, Clinical Infectious Diseases, vol.36, issue.6, pp.687-696, 2003.
DOI : 10.1086/368083

R. Perrillo, H. Hann, D. Mutimer, B. Willems, N. Leung et al., Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus, Gastroenterology, vol.126, issue.1, pp.81-90, 2004.
DOI : 10.1053/j.gastro.2003.10.050

M. Peters, H. Hw, H. Martin, P. Heathcote, E. Buggisch et al., Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary???s Hospital, London, England); C. Trepo (Hopital H??tel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ)., Gastroenterology, vol.126, issue.1, pp.91-101, 2004.
DOI : 10.1053/j.gastro.2003.10.051

F. Zoulim, Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy?, Hepatology, vol.38, issue.6, pp.1353-1355, 2003.
DOI : 10.1053/jhep.2003.10001

P. Angus, R. Vaughan, S. Xiong, H. Yang, W. Delaney et al., Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase, Gastroenterology, vol.125, issue.2, pp.292-297, 2003.
DOI : 10.1016/S0016-5085(03)00939-9

J. Villeneuve, D. Durantel, S. Durantel, C. Westland, S. Xiong et al., Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient, Journal of Hepatology, vol.39, issue.6, pp.1085-1089, 2003.
DOI : 10.1016/j.jhep.2003.09.022

L. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell et al., Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection, Science, vol.284, issue.5415, pp.825-829, 1999.
DOI : 10.1126/science.284.5415.825